<DOC>
	<DOCNO>NCT00831467</DOCNO>
	<brief_summary>The purpose study determine efficacy safety new vaccine hormone refractory prostate cancer</brief_summary>
	<brief_title>Safety Efficacy Trial RNActive®-Derived Prostate Cancer Vaccine Hormone Refractory Disease</brief_title>
	<detailed_description>Immunotherapy prostate cancer promise approach treatment advance recurrent form prostate cancer . Recently , immunotherapy prostate cancer facilitate identification number prostate specific antigen express healthy tumor prostate tissue . For prostatectomized patient , antigen offer ideal target immunotherapy present tumor healthy tissue . The use prostate specific antigens cancer vaccine one attractive option cancer immunotherapy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Signed informed consent accordance GCP local regulatory requirement prior trial participation Male age ≥ 18 year ( Phase I II ) ≤ 75 year ( Phase II ) Histologically confirm diagnosis adenocarcinoma prostate , Gleason Score available Patients must treat hormonal therapy may treat surgery and/ radiation therapy Progressive disease define hormonerefractoriness rise PSA : Hormonerefractoriness : Defined rise PSA and/or RECISTbased progression evaluable lesion , and/or increase number hotspot bone scan , patient castrate level testosterone . This castrated level may obtain orchiectomy , LHRH analog ± antiandrogen . Antiandrogen must discontinue least 4 week study entry exclude withdrawal effect . Rise PSA : Defined rise PSA level three consecutive time point ( PSA rise nadir , separate &gt; 1 week , PCWG2 criterion ) Presence metastatic disease acceptable ECOG performance status 0 1 Life expectancy &gt; 12 month assess investigator Adequate organ function : Bone marrow function : Hemoglobin ≥ 10 g/dL ; Leukocytes ≥ 3000/µL ; Lymphocytes ≥ 1000/µL ; Absolute neutrophil count ≥ 1500/µL ; Platelet count ≥ 100000/µL Hepatic : AST ALT ≤ 2.5 time upper limit normal ( ULN ) ; Bilirubin ≤ 1.5 ULN Renal : Creatinine ≤ 1.5 mg/dL creatinine clearance ≥ 60mL/min Concomitant LHRH therapy continuation acceptable May local palliative radiotherapy bone metastasis involve less 25 % bone marrow Patients require bisphosphonates time registration trial eligible ( therapy initiate least 28 day prior first study treatment administration ) must continue constant level study period . Patients childproducing potential must agree use contraception enrol study one month last immunization . Other histologic type prostate cancer ( transitional cell , small cell squamous cell cancer ) Symptomatic brain metastasis leptomeningeal involvement Patients receive currently receive chemo biological therapy prostate cancer Symptomatic congestive heart failure ( NYHA 3 4 ) ; unstable angina pectoris ; significant cardiac arrhythmia Pulmonary disease cause dyspnea fatigue normal activity History seizure , encephalitis multiple sclerosis Inflammatory bowel disease e.g . Crohn 's disease ulcerative colitis ; active diverticulitis Documented history active autoimmune disorder require systemic immunosuppressive therapy , ( e.g . sarcoidosis , lupus erythematosus , rheumatoid arthritis , glomerulonephritis systemic vasculitis ) , except autoimmune thyroiditis thyroid hormone replacement stable disease &gt; 1 year Primary secondary immune deficiency History allergy require medication Active drug abuse chronic alcoholism Clinically significant active infection Seropositive HIV , HBV HCV History malignancy last 5 year ( except basal cell carcinoma skin ) Uncontrolled medical condition consider high risk treatment investigational drug include unstable diabetes mellitus , venacavasyndrome , know ascites and/or pleural effusion , symptomatic pleural effusion treat puncture Renal insufficiency require dialysis Patients committed institution virtue order issue either judicial administrative authority</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Hormonal refractory prostate cancer</keyword>
	<keyword>RNA vaccine</keyword>
</DOC>